Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Influenza vaccine effectiveness within prospective cohorts of healthcare personnel in Israel and Peru 2016–2019
Vaccine, Volume 39, No. 47, Year 2021
Notification
URL copied to clipboard!
Description
Background: There are limited data on influenza vaccine effectiveness (IVE) in preventing laboratory-confirmed influenza illness among healthcare personnel (HCP). Methods: HCP with direct patient contact working full-time in hospitals were followed during three influenza seasons in Israel (2016–2017 to 2018–2019) and Peru (2016 to 2018). Trivalent influenza vaccines were available at all sites, except during 2018–2019 when Israel used quadrivalent vaccines; vaccination was documented by electronic medical records, vaccine registries, and/or self-report (for vaccinations outside the hospital). Twice-weekly active surveillance identified acute respiratory symptoms or febrile illness (ARFI); self-collected respiratory specimens were tested by real-time reverse transcription polymerase chain reaction (PCR) assay. IVE was 100 × 1-hazard ratio (adjusted for sex, age, occupation, and hospital). Results: Among 5,489 HCP who contributed 10,041 person-seasons, influenza vaccination coverage was 47% in Israel and 32% in Peru. Of 3,056 ARFIs in Israel and 3,538 in Peru, A or B influenza virus infections were identified in 205 (7%) in Israel and 87 (2.5%) in Peru. IVE against all viruses across seasons was 1% (95% confidence interval [CI] = −30%, 25%) in Israel and 12% (95% CI = −61%, 52%) in Peru. Conclusion: Estimates of IVE were null using person-time models during six study seasons in Israel and Peru. © 2021
Authors & Co-Authors
Thompson, Mark G.
United States, Atlanta
Centers for Disease Control and Prevention
Katz, Mark A.
Unknown Affiliation
Tinoco, Yeny O.
Peru, Lima
Naval Medical Research Unit No. 6
Shemer-Avni, Yonat
Israel, Beer-sheva
Ben-gurion University of the Negev
Ticona, Eduardo
Peru, Lima
Hospital Nacional Dos de Mayo
Martín, Emily Toth
United States, Ann Arbor
University of Michigan, Ann Arbor
Levine, Min Z.
United States, Atlanta
Centers for Disease Control and Prevention
Bravo Paredes, Eduar Alban
Peru, Lima
Hospital Nacional Cayetano Heredia
Arriola, Carmen
United States, Atlanta
Centers for Disease Control and Prevention
Dawood, Fatimah S.
United States, Atlanta
Centers for Disease Control and Prevention
Greenberg, David P.
Israel, Beer-sheva
Ben-gurion University of the Negev
Azziz-Baumgartner, Eduardo
United States, Atlanta
Centers for Disease Control and Prevention
Balicer, Ran D.
Unknown Affiliation
Statistics
Citations: 3
Authors: 13
Affiliations: 11
Identifiers
Doi:
10.1016/j.vaccine.2021.07.077
ISSN:
0264410X
Research Areas
Environmental
Health System And Policy
Study Design
Cohort Study